Compound

D1098 | sorafenib

Molecular Formula C21H16ClF3N4O3
Molecular Weight 464.8
Structure

Toxicity Dose Time Species Model Method Action Positive criterion Reference
MEMBRANE POTENTIAL 0.96±0.09 human qHTS-HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 1.23 human HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 2.25±0.63 rat hepatocytes MMP assay decrease IC50 163
MEMBRANE POTENTIAL 0.5 µM 30 mins mouse liver mitochondria Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) decrease EC20 36
RESPIRATION 283.4 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. decrease EC20 36
RESPIRATION ND 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. Negative EC20 36
SWELLING ND 30 mins mouse liver mitochondria swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling ) Negative EC20 36

Target Dose Time Species Model Method Action Positive criterion Reference
NADH:ubiquinone reductase 283.4 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. inhibit EC20 36
Succinate dehydrogenase ND 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. Negative EC20 36
Cytochrome c > 400 µM 30 mins mouse liver mitochondria Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline) release EC20 36

Pictogram Signal Statements Precautionary Statement Codes
Danger

Aggregated GHS information provided by 2 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H351 (50%): Suspected of causing cancer [Warning Carcinogenicity]


H360 (50%): May damage fertility or the unborn child [Danger Reproductive toxicity]


H361 (50%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]


H362 (50%): May cause harm to breast-fed children [Reproductive toxicity, effects on or via lactation]


H372 (50%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]


H402 (50%): Harmful to aquatic life [Hazardous to the aquatic environment, acute hazard]


H410 (50%): Very toxic to aquatic life with long lasting effects [Warning Hazardous to the aquatic environment, long-term hazard]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


P201, P202, P260, P263, P264, P270, P273, P281, P308+P313, P314, P391, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)


  • 100012-18-8 15216-EP2272827A1 15216-EP2298778A1
    15216-EP2311840A1 15216-EP2316832A1 15216-EP2316833A1
    1uwh 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl- 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-
    284461-73-0 3gcs 3heg
    4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide 4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N-METHYLPICOLINAMIDE
    4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido) phenoxy)-N-methylpicolinamide 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido)phenoxy)-N-methylpicolinamide 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate
    4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)- N-methylpyridine-2-carboxamide
    4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-picolinamide;tosylic acid 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide
    4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide;
    4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-N-methylpyridine-2-carboxamide 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methyl-pyridine-2-carboxamide
    461S730 4asd 9ZOQ3TZI87
    AB0019677 AB00933189-05 AB00933189-06
    AB00933189_08 AB1004622 AC-1674
    ACN-032355 ACT06732 AK163019
    AKOS005560229 AM20090614 AOB87782
    BAY 43-9006 BAY 43-9006 BAY 439006
    BAY 439006 BAY-43-0006 BAY-43-9006
    BAY-439006 BAY-54-9085 BAY43-9006
    BAY439006 BAY439006 BCP01767
    BCPP000064 BDBM16673 BRD-K23984367-001-01-8
    CHEBI:50924 CHEMBL1336 CS-1590
    CS0056 D08524 DB00398
    DTXSID7041128 EC 608-209-4 EN002709
    EX-A2894 FT-0650736 GTPL5711
    HMS2043A18 HMS3244A15 HMS3244A16
    HMS3244B15 HMS3656N20 HSDB 8173
    HY-10201 Hit compound, 8 J10391
    K00597a KS-0000009E Kinome_766
    LS-186067 LS-187021 LS-187788
    MCULE-6112506696 MFCD06411450 MLDQJTXFUGDVEO-UHFFFAOYSA-N
    N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea
    N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea NCGC00167488-01
    NCGC00167488-02 NCGC00167488-03 NCGC00167488-04
    NCGC00167488-05 NCGC00167488-07 NCGC00167488-14
    NSC-724772 NSC-747971 NSC747971
    Nexavar Nexavar (TN) (Bayer) Nexavar|||BAY 43-9006
    PB14443 Q-201728 Q421136
    QCR-65 SB19942 SC-19355
    SCHEMBL8218 SF-0529 SORAFENIB BASE
    SR-00000000529 SR-00000000529-1 STK627350
    SW202562-4 SYN1082 Sorafenib
    Sorafenib Sorafenib (Nexavar) Sorafenib (USAN/INN)
    Sorafenib [INN] Sorafenib [USAN:INN:BAN] Sorafenib free base (BAY-43-9006)
    Sorafenib, 4 Sorafenib-d3 Sorafinib
    UNII-9ZOQ3TZI87 Z89277543 ZINC1493878
    cid_216239 s7397 sorafenibum

    CAS Number 100012-18-8, 1130115-44-4, 1210608-86-8, 284461-73-0, 475207-59-1
    PubChem Compound 216239
    ChEBI 50924